Tests tumor samples from people treated with a gene-modified cell therapy
Checks tumor samples for the therapy's genetic marker in people with a second cancer.
Plain-language title generated from the registry record
Registry title: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Key facts
- Where
- Kumamoto and Toyokawa, JapanSee the 2 sites
Where in Japan
- KumamotoKumamoto, JapanNo longer taking part
- Toyokawa City HospitalToyokawa, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06357754
- Record updated
- 22 January 2026
- Original description
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.Read full original descriptionShow less
Protocol for Transgene Assay Service
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Inclusion: Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing; Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
Exclusion: Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy; Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.